Arzerra ofatumumab regulatory update

Genmab said FDA accepted and granted Priority Review to an sBLA from Novartis for Arzerra ofatumumab to treat relapsed chronic lymphocytic leukemia (CLL) in combination with fludarabine and cyclophosp...